More Starpharma Holdings Limited news
Starpharma Holdings LimitedASX: SPL

VivaGel BV US FDA Appeal Outcome

Feb 18, 2024 at 10:57 PM EST · Issued by Starpharma Holdings Limited

Filed with ASX · Feb 18, 2024 at 10:57 PM EST

On 6ix: 6ix.com/news/vivagel-bv-us-fda-appeal-outcome

Starpharma Holdings Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Starpharma Holdings Limited on 6ix

Earlier from Starpharma

  • Viraleze shows antiviral efficacy in COVID-19 patientsJan 28, 2024
  • VivaGel BV sales and distribution agreement MENA regionJan 22, 2024
  • Positive DEP docetaxel Phase 2 resultsDec 18, 2023
  • AGM Chairman's address and CEO presentationNov 29, 2023
  • Starpharma announces new CEO, Ms Cheryl MaleyNov 9, 2023

Later from Starpharma

  • S&P DJI Announces March 2024 Quarterly RebalanceMar 1, 2024
  • Starpharma and Medicxi Partnership Petalion TherapeuticsApr 7, 2024
  • Starpharma Business UpdateMay 22, 2024
  • Positive final DEP irinotecan Phase 2 clinical trial resultsMay 27, 2024
  • Annual Report to shareholdersAug 21, 2024
All Starpharma news releases↗

Follow Starpharma into a list and get an email when it puts out news.

Follow Starpharma
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer